Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
KOD 
Kodiak Sciences Inc (KOD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/07/2025: KOD (4-star) is a STRONG-BUY. BUY since 68 days. Profits (82.63%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7.25
1 Year Target Price $7.25
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 3 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 545.26% | Avg. Invested days 46 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 433.19M USD | Price to earnings Ratio - | 1Y Target Price 7.25 |
Price to earnings Ratio - | 1Y Target Price 7.25 | ||
Volume (30-day avg) 6 | Beta 2.42 | 52 Weeks Range 1.92 - 11.60 | Updated Date 08/7/2025 |
52 Weeks Range 1.92 - 11.60 | Updated Date 08/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Earnings Date
Report Date 2025-08-12 | When Before Market | Estimate -1.04 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.1% | Return on Equity (TTM) -108.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 355645046 | Price to Sales(TTM) - |
Enterprise Value 355645046 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52763500 | Shares Floating 32344470 |
Shares Outstanding 52763500 | Shares Floating 32344470 | ||
Percent Insiders 5.52 | Percent Institutions 81.49 |
Upturn AI SWOT
Kodiak Sciences Inc
Company Overview
History and Background
Kodiak Sciences Inc. is a biopharmaceutical company founded in 2006. It focuses on developing novel therapies to treat chronic, high-prevalence retinal diseases. Initially, the company focused on its Antibody Biopolymer Conjugate (ABC) platform, designed to extend the durability and improve the delivery of ophthalmic therapies.
Core Business Areas
- Ophthalmology: Focuses on developing treatments for retinal diseases, primarily using its ABC Platform. This platform is the foundation for their lead product candidate, tarcocimab tedromer (KSI-301).
Leadership and Structure
Kodiak Sciences is led by Victor Perlroth, MD, as CEO. The company's structure includes research and development, clinical operations, and administrative functions, typical of a biotechnology firm.
Top Products and Market Share
Key Offerings
- Tarcocimab Tedromer (KSI-301): KSI-301 is Kodiak's lead product candidate, an anti-VEGF therapy utilizing the ABC platform designed for extended durability in treating wet AMD, DME, and RVO. As a pre-commercial product, it currently holds no market share. Key competitors include Eylea (Regeneron), Lucentis and Vabysmo (Roche/Genentech), and Beovu (Novartis).
Market Dynamics
Industry Overview
The ophthalmology market, particularly for retinal diseases, is substantial and growing due to an aging population and increasing prevalence of diabetes. The market is competitive with established players and biosimilar threats.
Positioning
Kodiak Sciences aims to differentiate itself with KSI-301 by offering longer treatment intervals compared to existing anti-VEGF therapies, potentially reducing the burden of frequent injections for patients. Their success depends on clinical trial outcomes and regulatory approvals.
Total Addressable Market (TAM)
The global market for retinal disease therapies is estimated to be in the tens of billions of dollars annually. Kodiak is attempting to capture a significant portion of this by addressing the unmet need for longer-lasting treatments. If approved the TAM could be $12 billion by 2028
Upturn SWOT Analysis
Strengths
- Proprietary ABC platform with potential for extended durability
- Targeting large and growing ophthalmology market
- Experienced management team
Weaknesses
- Single lead product candidate (KSI-301) creates high dependence
- Clinical trial failures and delays
- High cash burn rate
- Limited revenue stream
Opportunities
- Positive clinical trial data could lead to rapid market adoption
- Potential for partnerships or acquisitions by larger pharmaceutical companies
- Expansion of ABC platform to other therapeutic areas
Threats
- Clinical trial failures or regulatory disapproval
- Competition from established anti-VEGF therapies and biosimilars
- Changing reimbursement landscape
- Possible fund raising efforts which could delute shareholders.
Competitors and Market Share
Key Competitors
- REGN
- RHHBY
- NVS
Competitive Landscape
Kodiak faces intense competition from established players with approved anti-VEGF therapies. Its advantage lies in potentially longer treatment intervals if KSI-301 is successful.
Growth Trajectory and Initiatives
Historical Growth: Historically, growth has been driven by the advancement of KSI-301 through clinical trials.
Future Projections: Future growth hinges on successful clinical trial outcomes, regulatory approval, and commercial launch of KSI-301. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing KSI-301 through Phase 3 clinical trials and exploring potential partnerships.
Summary
Kodiak Sciences is a high-risk, high-reward biopharmaceutical company dependent on the success of its lead product candidate, KSI-301. The company's strengths lie in its innovative ABC platform and focus on a large market. Its weaknesses include reliance on a single product, while they must be aware of well-established competitors. Success depends on positive clinical trial data and navigating the complex regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Analyst Reports
- Industry Publications
- Kodiak Sciences Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share data is based on estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://kodiak.com |
Full time employees 113 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.